Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inadequate response to conventional therapy including corticosteroids or are intolerant to, or have medical contraindications for conventional therapies
UC diagnosed prior to screening, based on a biopsy collected at endoscopy
Moderate to severe active UC with total Mayo score of 6 to 12, inclusive at baseline, and endoscopic Mayo sub-score, greater than or equal to 2
Adenomatous polyps removed within last 5 years or at the screening visit prior to the first drug treatment
Extensive colitis for ≥ 8 years, or disease limited to the left side of the colon for ≥10 years should have a colonoscopy to exclude the presence of dysplasia within 1 year prior to study inclusion or a colonoscopy to exclude the presence of malignancy at the screening visit
No history of untreated latent or active Tuberculosis (TB) prior to screening
Negative stool results for enteric pathogens
You may not be if
History of asthma
History of autoimmune diseases
History of hypertension
Clareo Health | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
